Market Place
Sourcing Support
Upneeq Wins 2024 Shape Skin "Best for Lift" Award
17 May 2024 //
BUSINESSWIRE
RVL Completes Financial Restructuring
27 Nov 2023 //
GLOBENEWSWIRE
RVL Pharma Announces Prepackaged Reorganization of Certain U.S. Subsidiaries
12 Oct 2023 //
GLOBENEWSWIRE
RVL Pharma to Present at H.C. Wainwright 25th Annual Investment Conference
23 Aug 2023 //
GLOBENEWSWIRE
RVL Pharma Announces $5M Direct Offering Priced At-the-Market under Nasdaq Rules
16 Aug 2023 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc Provides Business Update
05 Jul 2023 //
GLOBENEWSWIRE
RVL Pharma Announces Result of Proposal to Approve Waiver of Offer Obligations
15 Jun 2023 //
GLOBENEWSWIRE
RVL Pharmaceuticals Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc to Discuss 1Q 2023 FYR and Provide Commercial Update
04 May 2023 //
GLOBENEWSWIRE
RVL Pharmaceuticals Announces that Upneeq Wins Best Eye Drop
03 Apr 2023 //
GLOBENEWSWIRE
RVL Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
20 Mar 2023 //
GLOBENEWSWIRE
RVL to Discuss Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
RVL Announces Preliminary Fourth Quarter Sequential Growth of 21%
09 Jan 2023 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic
01 Dec 2022 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc to Discuss 3Q FYR and Provide Commercial Update
03 Nov 2022 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc to Present at the H.C. Wainwright 24th Annual Global
30 Aug 2022 //
GLOBENEWSWIRE
Revision Skincare Announces Strategic Partnership with RVL Pharmaceuticals, Inc.
29 Aug 2022 //
PRNEWSWIRE
RVL Pharmaceuticals plc Reports Q2 2022 Result; Provides Commercial Update
11 Aug 2022 //
GLOBENEWSWIRE
RVL Pharma to Discuss Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing
04 Aug 2022 //
GLOBENEWSWIRE
RVL Pharma Announces Preliminary Q2 2022 UPNEEQ Net Product Sales Results
07 Jul 2022 //
GLOBENEWSWIRE
RVL Pharma Announces Preliminary Q2 2022 UPNEEQ Net Product Sales Results
07 Jul 2022 //
PRNEWSWIRE
RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
16 Jun 2022 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc to Present at Upcoming Conferences
16 May 2022 //
GLOBENEWSWIRE
RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
RVL Pharma to Discuss Q1 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
RVL Pharma Announces Preliminary Q1 2022 UPNEEQ Net Product Sales Results
06 Apr 2022 //
GLOBENEWSWIRE
RVL Pharma Reports Q4 and Full Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
RVL Pharma to Discuss Q4 and Full Year 2021 Financial Results
23 Mar 2022 //
GLOBENEWSWIRE
RVL Pharma to Present at the Barclays Global Healthcare Conference 2022
09 Mar 2022 //
GLOBENEWSWIRE
